MAVENCLAD

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug MAVENCLAD contains one active pharmaceutical ingredient (API):

1 Cladribine
UNII 47M74X9YT5 - CLADRIBINE

Cladribine is a nucleoside analogue of deoxyadenosine. In resting cells cladribine causes DNA single-strand breaks, rapid nicotinamide adenine dinucleotide consumption, ATP depletion and cell death.

Read about Cladribine

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
MAVENCLAD Tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01BB04 Cladribine L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BB Purine analogues
Discover more medicines within L01BB04
L04AA40 L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA40

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 11603Q, 11604R, 11611D
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 525420020051407, 525420020051507, 525420020051607
Country: CA Health Products and Food Branch Identifier(s): 02470179
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 4683-MEE-0419
Country: EE Ravimiamet Identifier(s): 1752443, 1752454, 1752465, 1752476, 1752487, 1752498
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 1171212001
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 130242, 137721, 155121
Country: FR Base de données publique des médicaments Identifier(s): 65820786
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 347911, 347912, 347913
Country: HK Department of Health Drug Office Identifier(s): 65910
Country: IE Health Products Regulatory Authority Identifier(s): 88966, 88967, 88968
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 8148, 8149, 8150
Country: IT Agenzia del Farmaco Identifier(s): 045615010, 045615022, 045615034, 045615046, 045615059, 045615061
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1083745, 1083746, 1083747, 1083748, 1083749, 1083750
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 20042
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100393522
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W64663001, W64663002, W64663003, W64663004, W64663005, W64663006
Country: SG Health Sciences Authority Identifier(s): 15691P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699808090409, 8699808090416, 8699808090423, 8699808090430, 8699808090447, 8699808090454
Country: US FDA, National Drug Code Identifier(s): 44087-4000

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.